PDF(Pubmed)
Abstract：
Sumeet SidhuObjectives Breast cancer is the leading cause of cancer-related deaths in women. Estrogen (ER) and progesterone receptor (PR) status and Her2 overexpression are major determinants in therapeutic decision making. Triple-negative breast cancers (TNBCs) have limited treatment options. Androgen receptor (AR) expression opens up therapeutic avenues for these patients. The aim of this article was to study the immunohistochemical expression of ARs in ER and PR Negative breast carcinomas and to correlate AR expression with various clinical, histopathological, and other immunohistochemical parameters. Materials and Methods It is a cross-sectional study including 105 ER and PR Negative cases of breast carcinoma. Clinical parameters, histopathology, and immunohistochemical expression of AR, Her2, and Ki67 were analyzed in all cases. Results AR expression was observed in 63.8% of ER and PR Negative breast cancers. In this group, AR expression was strongly associated with Her2 co-expression (89.2%) as compared to TNBCs (45.8%); p -value = 0.0002. Significant correlation was also observed between AR expression and tumor necrosis ( p -value = 0.034) and postmenopausal status ( p = 0.007). Conclusion Our study shows that significant proportion of ER and PR Negative breast carcinomas (ER- PR- Her2+ and TNBCs) show AR expression. We strongly recommend routine evaluation of all hormone receptor-negative breast carcinomas for AR status by immunohistochemistry.
摘要：
SumeetSidhuObjectives乳腺癌是女性癌症相关死亡的主要原因。雌激素（ER）和孕激素受体（PR）状态和Her2过表达是治疗决策的主要决定因素。三阴性乳腺癌（TNBC）的治疗选择有限。雄激素受体（AR）的表达为这些患者开辟了治疗途径。本文的目的是研究AR在ER和PR阴性乳腺癌中的免疫组织化学表达，并将AR表达与各种临床，组织病理学,和其他免疫组织化学参数。材料与方法这是一项横断面研究，包括105例ER和PR阴性的乳腺癌病例。临床参数,组织病理学,和AR的免疫组织化学表达，在所有病例中分析Her2和Ki67。结果63.8%的ER和PR阴性乳腺癌组织中有AR表达。在这个群体中,与TNBC(45.8%)相比,AR表达与Her2共表达(89.2%)强烈相关;p值=0.0002。在AR表达与肿瘤坏死（p值=0.034）和绝经后状态（p=0.007）之间也观察到显着相关性。结论我们的研究表明，ER和PR阴性乳腺癌（ER-PR-Her2和TNBC）的显着比例显示AR表达。我们强烈建议通过免疫组织化学对所有激素受体阴性乳腺癌的AR状态进行常规评估。
